Strategic Initiative
Slingshot members are tracking this corporate initiative:
Emergent Bio (EBS) and Integrated Biotherapeutics Announce Deal to Develop Hyperimmunoglobulin for Filovirus-Associated Hemorrhagic Fever
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
EBS |
|
|
Integrated Biotherapeutics |
|
|
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Nov 15, 2016 Projected Implementation: Q1, 2017 Relevance Tracked Until: Q1, 2019
Related Projects
-
Don’t see a project related to the strategic initiative you care about?
Related Keywords
Exclusive Worldwide License Agreement, Proprietary Vaccine Antigens, Hyperimmunoglobulin, Filovirus, Hemorrhagic Fever